Royalty Report: Drugs, Nutraceutical, Biotechnology – Collection: 28052

$100.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 4

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 4

Primary Industries

  • Drugs
  • Nutraceutical
  • Biotechnology
  • Food

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 28052

License Grant
The UNIVERSITY granted the Licensee the exclusive, worldwide right and license to the technology for development, marketing and selling of reference standards for the Nutraceutical market and the identification and isolation of the constituents thereof and methodologies.
License Property
UNIVERSITY has developed and owns rights to Know-how, data, methods of analysis, trade secrets, technology, skill, and experience relating to the scientific investigation, extraction, purification of chemical constituents, analysis and development of reference standards from a wide variety of natural product sources which, to the extent not disclosed in issued patents, are
confidential and proprietary.

LIST OF NUTRACEUTICALS FOR ISOLATION OF MARKER COMPOUNDS

Duration

Name of the Plants

(Months)

No. of Compounds

Echinacea angustifolia

6-Jan

Kava (Piper methysticum)

6-Jan

Milk thistle (Silybum marianum)

6-Jan

Cat’s claw (Uncaria tomentosa)

6-Jan

10 compounds

Feverfew (Tanactum parthenium)

12-Jul

Astraglus spp

12-Jul

Ginkqo biloba

12-Jul

Black cohosh (Cimicifuga racemosa)

12-Jul

10 compounds

Valariana officinalis

13-18

Ginseng root (Panax quinquefolum)

13-18

Dong quai (Angelica sinensis)

13-18

Siberian ginseng (E. senticosus)

13-18

10 compounds

No. of plants=12

Months=18

Compounds=30

(each around 500 mg)

IPSCIO Record ID: 28225

License Grant
Party A hereby assigns, transfers and sets over to Party B all right, title and interest to all patents, registrations and/or applications filed by Party A or its agent in any jurisdiction in the Asia Pacific Region.  Party A hereby grants Party B a non-exclusive, perpetual, royalty- free (except pursuant to royalty consideration) and fully-paid license (i) to use, modify, reproduce, display, make, deploy and otherwise exploit the Patented Technology, Know-How and the associated  intellectual property rights therein in the manufacturing of the Products, and (ii) to sublicense any of the foregoing rights in any jurisdiction in the Asia Pacific Region (collectively, the Technology License), each during the term of this Agreement.  Party A hereby grants Party B an exclusive, perpetual, royalty-free (except pursuant to royalty consideration) and fully-paid license (i) to use the Licensed Marks in the Asia Pacific Region and (ii) to sublicense any of the foregoing rights pursuant to Section 14 in any jurisdiction in the Asia Pacific Region (collectively, the Trademark License), each during the term of this Agreement. Party A hereby grants to Party B an exclusive and perpetual right and license to market, promote and distribute (the Distribution Right) the Product in the  Asia Pacific Region on the terms and conditions set out below during the term of this Agreement.
License Property
Product means the dietary supplements, functional foods and pharmaceuticals derived from natural plant extracts produced by Party B or any sublicensee, contractor or other third party using the Patented Technology.   The technology enables the precise identification and consistent replication of the active ingredients from the natural plant extracts that are scientifically believed to provide the desired health benefits.

Pharmaceutical Grade Botanical Drugs       04/15/97     28131/97          Issued

Pharmaceutical Grade Echinacea             10/23/98     13634/99          Pending

Pharmaceutical Grade Ginkgo Biloba         10/23/98     13633/99          Pending

Pharmaceutical Grade Ginseng               10/23/98     11183/99          Pending

Pharmaceutical Grade Saw Palmetto,         10/23/98     13635/99          Pending

Serenoa Repens

Pharmaceutical Grade St. John's Wort       10/23/98     13631/99          Pending

Pharmaceutical Grade Valerian, Black       10/23/98     13632/99          Pending

Cohosh, Vitex Agnus-Castus, Bilberry and Milk Thistle

Field of Use
This agreement pertains to the medical industry.

IPSCIO Record ID: 29071

License Grant
U.S. University granted to the Company an exclusive worldwide license to certain inventions and patents relating to pharmacologically active elements of a muira puama extract and ion channel modulators from natural sources.
License Property
The biopharmaceutical company focused on the identification, acquisition, development and eventual commercialization of innovative plant derived pharmaceutical and nutraceutical compounds targeting cachexia, obesity and diabetes. Licensee entered into an exclusive worldwide licensing Agreement with University the Licensor, for certain patented inventions related to pharmacologically active elements of a muira puama plant extract and ion channel modulators from natural sources.

United States patents 5,234,947 and 5,516,516 entitled “Potassium channel activating compounds and methods of use thereof” and “Method of preparing muira puama extract and its use for decreasing body fat percentage and increasing lean muscle mass”, respectively (“the Existing Patents”).

Field of Use
“Field” shall mean medical, pharmacological, therapeutic, prophylactic, nutritional and research applications of muira puama extract, any of its chemical or biological constituents, and ion channel modulators from natural sources.

IPSCIO Record ID: 6141

License Grant
In connection with the acquisition of assets from CampaMed LLC, the Licensee entered into a separate agreement with the Licensor that obligates the Licensee to pay royalties in connection with the sale or licensing of any product that contains any compound, substance or ingredient derived or isolated from the Uncaria tomentosa vine such as our proprietary product AC-11, or its predecessor C-MED-100 (collectively referred to herein as AC-11.)
License Property
AC-11 is a bioactive form of the medicinal herb known as Uncaria tomentosa which is indigenous to the Amazon rainforest and other tropical areas of South and Central America.  Our nutritional supplement product contains our patented compound AC-11 which is derived from the rainforest botanical Uncaria tomentosa. Our product competes with other products on the market that contain Uncaria tomentosa as an ingredient.
Field of Use
The rights granted apply to the medicinal herb from South and Central America for the use of nutritional supplements.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.